

Resource Summary Report

Generated by [nidm-terms](#) on Aug 20, 2026

BV650 Rat Anti-Mouse CD4

RRID:AB_2716859

Type: Antibody

Proper Citation

BD Biosciences Cat# 563747, RRID:AB_2716859

Antibody Information

URL: http://antibodyregistry.org/AB_2716859

Proper Citation: BD Biosciences Cat# 563747, RRID:AB_2716859

Target Antigen: CD4

Host Organism: rat

Clonality: monoclonal

Comments: Flow cytometry

Antibody Name: BV650 Rat Anti-Mouse CD4

Description: This monoclonal targets CD4

Target Organism: mouse

Clone ID: RM4-5

Antibody ID: AB_2716859

Vendor: BD Biosciences

Catalog Number: 563747

Record Creation Time: 20250819T230251+0000

Record Last Update: 20250820T040720+0000

Ratings and Alerts

No rating or validation information has been found for BV650 Rat Anti-Mouse CD4.

No alerts have been found for BV650 Rat Anti-Mouse CD4.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 18 mentions in open access literature.

Listed below are recent publications. The full list is available at [nidm-terms](#) .

Rodríguez-Guilarte L, et al. (2026) Regulation of antiviral immunity by PD-1 during respiratory syncytial virus infection and upon vaccination. *iScience*, 29(6), 116157.

Cheng BY, et al. (2026) Pharmacologic glycoengineering of Fc γ receptor IIIa enhances force-resistant IgG-Fc γ R interactions and anti-tumor antibody efficacy. *Immunity*, 59(7), 2030.

Zheng MZM, et al. (2026) Immunodominance is a poor predictor of vaccine-induced T follicular helper cell quality. *EBioMedicine*, 125, 106185.

Onimus A, et al. (2026) Taxane chemotherapy promotes response to TIM-3 checkpoint blockade via STING-mediated ER stress and HMGB1 secretion. *Cell reports. Medicine*, 7(5), 102788.

Cohen JN, et al. (2025) Regulatory T cells in skin utilize the Cxcr4-Cxcl12 axis to promote hair follicle regeneration. *Cell reports*, 44(11), 116467.

Deng C, et al. (2024) Extracellular-vesicle-packaged S100A11 from osteosarcoma cells mediates lung premetastatic niche formation by recruiting gMDSCs. *Cell reports*, 43(2), 113751.

Hänggi K, et al. (2024) Interleukin-1 β release during necrotic-like cell death generates myeloid-driven immunosuppression that restricts anti-tumor immunity. *Cancer cell*, 42(12), 2015.

Chen XY, et al. (2024) Arming oncolytic M1 virus with gasdermin E enhances antitumor efficacy in breast cancer. *iScience*, 27(11), 111148.

Weckel A, et al. (2023) Long-term tolerance to skin commensals is established neonatally through a specialized dendritic cell subgroup. *Immunity*, 56(6), 1239.

Merana GR, et al. (2022) Intestinal inflammation alters the antigen-specific immune response to a skin commensal. *Cell reports*, 39(9), 110891.

Fettig NM, et al. (2022) Inhibition of Th1 activation and differentiation by dietary guar gum ameliorates experimental autoimmune encephalomyelitis. *Cell reports*, 40(11), 111328.

Arai M, et al. (2022) Protocol to evaluate cell lineage stability of mouse natural and induced regulatory T cells using bisulfite sequencing. *STAR protocols*, 3(4), 101694.

de Mingo Pulido Á, et al. (2021) The inhibitory receptor TIM-3 limits activation of the cGAS-STING pathway in intra-tumoral dendritic cells by suppressing extracellular DNA uptake. *Immunity*, 54(6), 1154.

Matias MI, et al. (2021) Regulatory T cell differentiation is controlled by ?KG-induced alterations in mitochondrial metabolism and lipid homeostasis. *Cell reports*, 37(5), 109911.

Chopp LB, et al. (2020) An Integrated Epigenomic and Transcriptomic Map of Mouse and Human ?? T Cell Development. *Immunity*, 53(6), 1182.

Leech JM, et al. (2019) Toxin-Triggered Interleukin-1 Receptor Signaling Enables Early-Life Discrimination of Pathogenic versus Commensal Skin Bacteria. *Cell host & microbe*, 26(6), 795.

Celis-Gutierrez J, et al. (2019) Quantitative Interactomics in Primary T Cells Provides a Rationale for Concomitant PD-1 and BTLA Coinhibitor Blockade in Cancer Immunotherapy. *Cell reports*, 27(11), 3315.

de Mingo Pulido Á, et al. (2018) TIM-3 Regulates CD103+ Dendritic Cell Function and Response to Chemotherapy in Breast Cancer. *Cancer cell*, 33(1), 60.